Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE006 (GBR) (Dr. Rossi)
· consented 2023-02-21
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-03-27 (study day 384); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-03-30 (study day 387); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-04-19 (study day 407); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-06-25 (study day 474); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-08-28 (study day 538); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: UNKNOWN; onset 2024-09-28 (study day 569); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.